Trial Profile

A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odanacatib (Primary)
Indications Bone cancer; Postmenopausal osteoporosis
Focus Pharmacodynamics
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

05 Jan 2012 Actual initiation date changed from Feb 2010 to Dec 2009 as reported by ClinicalTrials.gov.
24 May 2010 Actual patient number (44) added as reported by ClinicalTrials.gov.
24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com